CDTX Valuation

Cidara Therapeutics Inc

Add to Watchlist

Advanced Chart

75.470

+6.76(9.838%)1D

Overview
Forecast
Valuation
Earnings

CDTX Relative Valuation

CDTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CDTX is overvalued; if below, it's undervalued.

Historical Valuation

Cidara Therapeutics Inc (CDTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.20. The fair price of Cidara Therapeutics Inc (CDTX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：75.47

Fair

-10.89

Trailing

Forward

-8.98

EV/EBITDA

Cidara Therapeutics Inc. (CDTX) has a current EV/EBITDA of -8.98. The 5-year average EV/EBITDA is -0.47. The thresholds are as follows: Strongly Undervalued below -4.32, Undervalued between -4.32 and -2.40, Fairly Valued between 1.45 and -2.40, Overvalued between 1.45 and 3.38, and Strongly Overvalued above 3.38. The current Forward EV/EBITDA of -8.98 falls within the Strongly Undervalued range.

-8.22

EV/EBIT

Cidara Therapeutics Inc. (CDTX) has a current EV/EBIT of -8.22. The 5-year average EV/EBIT is -1.31. The thresholds are as follows: Strongly Undervalued below -5.20, Undervalued between -5.20 and -3.26, Fairly Valued between 0.63 and -3.26, Overvalued between 0.63 and 2.57, and Strongly Overvalued above 2.57. The current Forward EV/EBIT of -8.22 falls within the Strongly Undervalued range.

0.00

Cidara Therapeutics Inc. (CDTX) has a current PS of 0.00. The 5-year average PS is 59.52. The thresholds are as follows: Strongly Undervalued below -358.97, Undervalued between -358.97 and -149.73, Fairly Valued between 268.76 and -149.73, Overvalued between 268.76 and 478.01, and Strongly Overvalued above 478.01. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-13.45

P/OCF

Cidara Therapeutics Inc. (CDTX) has a current P/OCF of -13.45. The 5-year average P/OCF is -2.32. The thresholds are as follows: Strongly Undervalued below -6.96, Undervalued between -6.96 and -4.64, Fairly Valued between 0.01 and -4.64, Overvalued between 0.01 and 2.33, and Strongly Overvalued above 2.33. The current Forward P/OCF of -13.45 falls within the Strongly Undervalued range.

-13.13

P/FCF

Cidara Therapeutics Inc. (CDTX) has a current P/FCF of -13.13. The 5-year average P/FCF is -1.38. The thresholds are as follows: Strongly Undervalued below -6.32, Undervalued between -6.32 and -3.85, Fairly Valued between 1.09 and -3.85, Overvalued between 1.09 and 3.56, and Strongly Overvalued above 3.56. The current Forward P/FCF of -13.13 falls within the Strongly Undervalued range.

Cidara Therapeutics Inc (CDTX) has a current Price-to-Book (P/B) ratio of 3.50. Compared to its 3-year average P/B ratio of 1.06 , the current P/B ratio is approximately 230.35% higher. Relative to its 5-year average P/B ratio of 1.20, the current P/B ratio is about 191.00% higher. Cidara Therapeutics Inc (CDTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -54.60%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -56.70% , the current FCF yield is about -100.00% lower.

3.50

P/B

Median3y

1.06

Median5y

1.20

-7.41

FCF Yield

Median3y

-54.60

Median5y

-56.70

Competitors Valuation Multiple

The average P/S ratio for CDTX's competitors is 0.00, providing a benchmark for relative valuation. Cidara Therapeutics Inc Corp (CDTX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CDTX.O

Cidara Therapeutics Inc

Niagen Bioscience Inc

USANA Health Sciences Inc

Nature's Sunshine Products Inc

Loss

3.80%

293.10M

Performance Decomposition

Market capitalization of CDTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CDTX in the past 1 year is driven by Unknown.